home / stock / clls / clls short
Short Information | Cellectis S.A. (NASDAQ:CLLS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 243,282 |
Total Actual Volume | 1,221,546 |
Short Trends | |
---|---|
Cover Days | 15 |
Short Days | 2 |
No Change Days | 3 |
Averages | |
---|---|
Average Short Volume | 12,164 |
Average Short Percentage | 22.67% |
Is there a CLLS Short Squeeze or Breakout about to happen?
See the CLLS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $1.97 | $2.05 | $2.0999 | $1.9636 | 44,377 | 8,300 | 18.7% |
07-02-2024 | $1.89 | $1.9 | $1.9216 | $1.88 | 14,222 | 7,464 | 52.48% |
07-01-2024 | $1.87 | $1.935 | $1.9599 | $1.85 | 37,536 | 11,164 | 29.74% |
06-28-2024 | $1.84 | $1.87 | $1.8995 | $1.84 | 36,154 | 15,998 | 44.25% |
06-27-2024 | $1.84 | $1.86 | $1.89 | $1.82 | 40,362 | 5,545 | 13.74% |
06-26-2024 | $1.86 | $1.87 | $1.87 | $1.82 | 99,975 | 22,233 | 22.24% |
06-25-2024 | $1.9 | $1.93 | $1.9304 | $1.86 | 44,701 | 1,125 | 2.52% |
06-24-2024 | $1.87 | $1.91 | $1.942 | $1.85 | 45,611 | 3,703 | 8.12% |
06-21-2024 | $1.85 | $1.89 | $1.93 | $1.82 | 205,112 | 24,003 | 11.7% |
06-20-2024 | $2.01 | $1.964 | $2.01 | $1.91 | 36,561 | 8,096 | 22.14% |
06-18-2024 | $2.01 | $2.015 | $2.12 | $1.98 | 127,503 | 18,445 | 14.47% |
06-17-2024 | $2.16 | $2.14 | $2.16 | $2.11 | 100,514 | 62,652 | 62.33% |
06-14-2024 | $2.24 | $2.25 | $2.3 | $2.1 | 54,631 | 20,493 | 37.51% |
06-13-2024 | $2.34 | $2.36 | $2.385 | $2.29 | 46,950 | 5,183 | 11.04% |
06-12-2024 | $2.48 | $2.42 | $2.48 | $2.375 | 89,986 | 7,956 | 8.84% |
06-11-2024 | $2.5 | $2.48 | $2.62 | $2.45 | 87,335 | 6,576 | 7.53% |
06-10-2024 | $2.54 | $2.57 | $2.57 | $2.46 | 77,635 | 5,684 | 7.32% |
06-07-2024 | $2.62 | $2.57 | $2.62 | $2.5602 | 11,919 | 4,172 | 35% |
06-06-2024 | $2.5931 | $2.67 | $2.69 | $2.5931 | 10,018 | 1,833 | 18.3% |
06-05-2024 | $2.78 | $2.73 | $2.78 | $2.65 | 10,444 | 2,657 | 25.44% |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publicatio...